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Specifically, they have generated isogenic pairs of cellDesperately Seeking Genotype-
lines from two primary normal human fibroblasts ex-Selective Anticancer Agents pressing up to six genetic elements that have been impli-
cated in human cancers: the human catalytic subunit of
the enzyme telomerase (hTERT), the Simian Virus 40
large T (LT) and small T (ST) oncoproteins, the Human
An approach has been described to identify new agents Papilloma Viral protein E6 and E7, and an allele of H-RAS
that selectively kill mammalian cells with multiple ge- (RASV12). They then screened the isogenic pairs with
netic abnormalities. Compounds of this type could over 23,000 compounds for selective cytotoxicity. While
lead to innovative cancer treatments based on tumor individuals who perform traditional in vitro high- and
genotype rather than by histology or anatomical lo- ultra high-throughput screens might not view this num-
cation. ber of compounds as especially large, it is substantial
for the more labor intensive cell-based assay, even one
Small molecules have historically been valuable re- simply measuring cell killing. Interestingly, the authors
agents to probe biologically intractable pathways and identify and describe nine compounds that have at least
to identify important cellular proteins. Consider the role 4-fold greater cytotoxicity to the TERT/LT/ST/ RASV12
aspirin had in the discovery of cyclooxygenases, norepi- cells compared with the parent primary fibroblasts.
nephrine and epinephrine in  and  adrenergic recep- While the identified compounds obviously reflect the
tors, bioamines in histamine receptors, nicotine in the chemical elements in the screened libraries, it intriguing
acetylcholine receptors, or rapamycin in mTOR. that four of the nine compounds are currently used in
Conventional drug discovery is dominated by ap- the clinic as antineoplastic agents. This validates the
proaches that exploit selected molecular targets and in notion that the general approach has the potential to
vitro assays. Cell-based or animal-based assays have identify newer agents that may have clinical utility. In
lagged substantially behind. Nonetheless, integrated addition to the known agents reported, the authors dis-
cell- and animal-based assays will undoubtedly become closed a new compound, erastin, which caused selec-
increasingly valuable as we begin to recognize that tive, rapid, nonapoptotic death to cells harboring both
much remains to be discovered about the complex bio- ST and oncogenic RASV12 and not to normal fibroblasts
logical networks that are responsible for human dis- or isogenic cells with other genotypes. A secondary
eases and that many human diseases involve multiple byproduct of this screening system was the observation,
rather than single genes. This is especially true for can- revealed by the identified compounds, that overex-
cer models, as genetic instability generates multiple and pressing hTERT and either E7 or LT increased expres-
dynamic genomic alterations. sion of topoisomerase 2 and that overexpressing
Many cancer researchers have emulated the drug dis- RASV12 and ST both increased endogenous expression
covery strategies taken by their nononcology brethren of topoisomerase 1.
and looked for compounds that affect a specific protein, As with all provocative articles, this contribution raises
often an oncogene, with obvious enzymatic activity that several interesting and unanswered questions. For ex-
is overexpressed or inappropriately activated. Nonethe- ample, the mechanism by which hTERT and E7 or LT
less, many of these protein targets are found in normal increased topoisomerase 2 expression is left unan-
tissues, and, thus, disrupting their activity could lead to swered. The authors observed that the rate of cell pro-
serious untoward effects and lack of disease specificity. liferation increased when each genetic element was
An attractive alternative approach inspired by studies introduced into fibroblasts. One class of identified com-
with yeast and popularized by Hartwell [1] and Kaelin pounds, group 1, had no clear genetic basis for their
[2] involves searching for genotype-selective antitumor tumorigenic cell selectivity, and the authors hypothe-
agents that become lethal to tumor cells only in the sized that group 1 compounds were simply selective for
presence of specific oncogenes or the absence of spe- dividing cells, in part because they targeted DNA or
cific tumor-repressor genes. This synthetic lethal strat- protein synthesis. If this hypothesis is true, the number
egy in an ideal situation should yield compounds with of compounds initially identified in the comparative iso-
exquisite selectivity against tumors with the altered ge- genic screening assays would seem rather small when
notype. The principle of synthetic lethality in its simplest one considers that it is conventional wisdom that most
form is illustrated in Figure 1A. Cells with intact and fully clinically used anticancer drugs act preferentially on rap-
functional genes A and/or B are viable, while cells in idly cycling cells. Moreover, the commonly used 1,990
which genes A and B are altered or deleted die. By compound National Cancer Institute diversity collection
analogy, in a synthetic lethal chemical screen one looks has a substantial number of agents that interact with
for killing only when cells have a specific genotype and DNA or have been examined as anticancer agents. Thus,
are exposed to a small molecule (Figure 1B). A number it would be interesting to evaluate all of the commonly
of compounds have already been reported that exhibit used anticancer agents with these isogenic lines to see
synthetic lethal properties [3, 4]. how many are selective for the tumorigenic phenotype.
Recently, Stockwell and colleagues [5] have taken Further clarification of the molecular target of erastin
would be valuable. While many investigators have fo-this elegant synthetic lethal approach to a higher level.
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to be a worthy undertaking. Another unanswered ques-
tion is why only partial resistance to camptothecin was
seen when small interfering RNA to topoisomerase 1
was introduced into TERT/LT/ST/RASV12 cells. Perhaps
there are other as yet unknown targets for the campto-
thecins that exist. We also do not know how important
the transfected gene expression stoichiometry is for the
ultimate sensitivity to particular agents. Nonetheless,
Dolma et al. [5] nicely illustrate the power of the synthetic
lethal approach for exposing agents with both unique
and potentially rich pharmacological properties. ItFigure 1. A Schematic Representation of the Traditional Synthetic
Lethal Strategy Used in Yeast Genetics Studies seems likely that many others will emulate their ap-
proach.(A) A and B represent different genes. When both normal genes are
present, the yeast are viable, signified by the smiling face. When
either gene A or B are altered or deleted (indicated with ), the
John S. Lazoorganism remains viable; when both genes are mutated, the lethal
phenotype, signified by the frowning face, occurs. Department of Pharmacology
(B) In a synthetic lethal chemical screen, the lethal phenotype occurs University of Pittsburgh
only when the organism has the altered gene or genes and is ex- Pittsburgh, Pennsylvania 15232
posed to a specific chemical agent. Thus, the concentration/dose-
response curve is shifted to the left in the cells that have the altered
or deleted gene(s). In some cases, the small molecule might inhibit
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Novel Carotenoids
Genetically Engineered tures are targets for modification and for mixing
substituents in the same molecule.in a Heterologous Host
Compounds can be synthesized in a modular way by
combining genes that comprise different branches of a
biosynthetic pathway, which are isolated from different
Carotenoids are commercially important pigments that organisms. Pioneering work following this approach was
are essential for human health. Diverse carotenoids carried out on the synthesis of novel polyketide antibiot-
have been identified, but availability has impeded eval- ics [1]. This strategy only works, however, when the
uation of their pharmaceutical potential. Molecular substrate specificity of a key biosynthetic enzyme is
techniques have been developed to produce specific such that it does not need to recognize the entire sub-
and novel carotenoids with improved biological activ- strate molecule but only certain regions of the molecule
ities. that are suitable for conversion. This is generally also
the case in carotenoid biosynthesis, and therefore this
Over the last few years, molecular procedures have been combinatorial approach was very successful in generat-
developed to engineer metabolic pathways. These in- ing numerous carotenoids including novel structures not
clude directed evolution by gene shuffling to alter the found before [2]. Among the carotenoids produced by
catalytic properties of enzymes, and combinatorial bio- combinatorial biosynthesis were carotenoids with im-
synthesis, i.e., coexpression of genes encoding different proved biological activity [3].
enzymes from related pathways. Both approaches have Highly homologous carotenogenic genes from related
successfully been applied to carotenoid biosynthesis. organisms may encode enzymes with modified sub-
The color of carotenoids is very helpful for the screening strate and/or product specificities [4], but this is a rare
and selection of transformants. Typical carotenoids occurrence. One experimental way of acquiring en-
zymes with extended catalytic properties for the synthe-consist of 40 carbon atoms with an extensive conju-
